IBD goes home: from telemedicine to self-administered advanced therapies.
Fiche publication
Date publication
juin 2021
Journal
Expert opinion on biological therapy
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Solitano V, Alfarone L, D'Amico F, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
Major challenges have been posed by the coronavirus disease 2019 pandemic in the routine management of patients with inflammatory bowel diseases (IBD). The need for constant monitoring of diseases activity and prompt adjustment of therapy have been balanced with the risk of contagion related to face-to-face consultations. Therefore, digital health initiatives have been pursued for safety reasons as vicarious instruments to avoid overcrowding of the IBD clinics. However, concerns and scepticism about the feasibility of digital health and telemedicine modalities limited their uptake in clinical practice in the pre-pandemic period.
Mots clés
home-based laboratory tests, inflammatory bowel diseases, self-administered therapy, telemedicine
Référence
Expert Opin Biol Ther. 2021 Jun 11;: